Ivabradina Mylan Pharma

Active Ingredient:: Ivabradine Oxalate
Origin:: EU

Ivabradina Mylan Pharma (Ivabradine Oxalate)

Q: What conditions is Ivabradina Mylan Pharma used for?

Ivabradina Mylan Pharma is prescribed to lower heart rate in adults with chronic stable angina pectoris and in patients with heart failure with reduced ejection fraction (NYHA class II‑III). By reducing the heart rate, it helps relieve angina symptoms and may improve functional capacity in heart‑failure patients.

Q: How does ivabradine work to lower heart rate?

Ivabradine selectively blocks the funny (If) current in the sino‑atrial node, the pacemaker of the heart. This inhibition slows the spontaneous depolarisation of pacemaker cells, leading to a reduced resting and exercise heart rate while leaving contractility and conduction pathways largely unchanged.

Q: What is the usual dose of Ivabradina Mylan Pharma?

The exact dose of Ivabradina Mylan Pharma is determined by the prescribing clinician based on the patient’s heart‑rate, clinical status, and tolerance. Dosage adjustments are made according to therapeutic response and any adverse effects, following the product’s prescribing information.

Q: Is Ivabradina Mylan Pharma safe during pregnancy or breastfeeding?

Safety data for ivabradine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies the potential risk to the fetus, and breastfeeding mothers should consult their healthcare provider before use.

Q: How do I order Ivabradina Mylan Pharma from GNH India?

To request Ivabradina Mylan Pharma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Q: How does ivabradine compare with beta‑blockers for heart‑rate control?

Both ivabradine and beta‑blockers lower heart rate, but ivabradine acts specifically on the If channel without affecting myocardial contractility or blood pressure, whereas beta‑blockers also reduce contractility and have broader sympathetic effects. Ivabradine is often considered when beta‑blockers are contraindicated or not tolerated.

Q: What are the storage requirements for Ivabradina Mylan Pharma tablets?

Ivabradina Mylan Pharma tablets should be stored at temperatures below 25 °C, in the original container, protected from moisture and direct sunlight. Maintaining these conditions helps preserve tablet potency and stability throughout its shelf life.

Q: How is Ivabradina Mylan Pharma administered?

The medication is taken orally, usually with or without food, as directed by the prescribing physician. Tablets should be swallowed whole with a glass of water and not crushed or chewed, to ensure proper absorption and effect.

Q: What are the most serious risks associated with ivabradine therapy?

The most serious risks include symptomatic bradycardia, atrial fibrillation, severe hypotension, and rare visual disturbances that may affect vision. Patients should be monitored for these events, especially during dose titration or when combined with other heart‑rate‑lowering agents.

Q: Who should not use Ivabradina Mylan Pharma?

Ivabradina Mylan Pharma is contraindicated in patients with acute decompensated heart failure, severe hypotension, sick‑sinus syndrome, or a resting heart rate below 60 bpm. It should also be avoided in individuals with known hypersensitivity to ivabradine or any of the tablet’s excipients.

Ivabradine, the active ingredient in Ivabradina Mylan Pharma, is a If channel inhibitor presented as a tablet for oral use. It treats chronic stable angina pectoris and heart failure with reduced ejection fraction in appropriate adult patients.

GNH India supplies Ivabradina Mylan Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Mylan S.P.A.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Ivabradina Mylan Pharma acts on the cardiac If current to lower heart rate in conditions where rate control improves outcomes.
Chronic stable angina pectoris: reduces the frequency of angina attacks by decreasing myocardial oxygen demand.
Heart failure with reduced ejection fraction (NYHA class II‑III): improves symptoms and may lower hospitalization risk.
Patients unable to tolerate beta‑blockers: provides heart‑rate reduction without affecting contractility or intracardiac conduction.

How It Works

Ivabradine selectively inhibits the funny (If) current in the sino‑atrial node, slowing depolarisation of pacemaker cells. This reduces spontaneous heart‑rate generation while preserving myocardial contractility and normal atrioventricular conduction, resulting in a lower resting and exercise heart rate without significant blood‑pressure changes.

Side Effects

Adverse reactions may be observed with ivabradine therapy.

Common Side Effects

Visual disturbances (phosphenes or luminous phenomena)
Bradycardia (resting heart rate <50 bpm)
Headache
Dizziness or light‑headedness
Fatigue
Nausea

Serious or Rare Side Effects

Symptomatic bradyarrhythmias requiring medical intervention
Atrial fibrillation or other supraventricular tachyarrhythmias
Severe hypotension
Persistent visual loss or retinal disturbances
Allergic skin reactions (rash, pruritus)

Precautions & Warnings

Before prescribing Ivabradina Mylan Pharma, clinicians should consider several safety measures.
Assess baseline heart rate: ensure resting rate ≥60 bpm before initiation.
Monitor ECG: watch for bradycardia or new arrhythmias during therapy.
Caution in hepatic impairment: dose adjustment may be required.
Avoid in severe hypotension or sick‑sinus syndrome.
Contraindicated in patients with acute decompensated heart failure.
Store at below 25°C: keep in the original pack, protect from moisture.

Avoid Interactions

Ivabradina Mylan Pharma can interact with several drug classes.

Major Interactions (Avoid)

Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase ivabradine exposure.
Concomitant bradycardic agents (beta‑blockers, digoxin, diltiazem, verapamil): risk of excessive heart‑rate reduction.
CYP3A4 inhibitors combined with diltiazem/verapamil: may cause severe bradycardia.

Moderate Interactions (Monitor Closely)

CYP3A4 inducers (rifampin, carbamazepine, phenytoin): may reduce efficacy.
Diuretics causing electrolyte shifts: monitor for arrhythmia risk.
Antihypertensive agents: observe for additive blood‑pressure lowering effects.

Frequently Asked Questions

Ivabradina Mylan Pharma is prescribed to lower heart rate in adults with chronic stable angina pectoris and in patients with heart failure with reduced ejection fraction (NYHA class II‑III). By reducing the heart rate, it helps relieve angina symptoms and may improve functional capacity in heart‑failure patients.

Ivabradine selectively blocks the funny (If) current in the sino‑atrial node, the pacemaker of the heart. This inhibition slows the spontaneous depolarisation of pacemaker cells, leading to a reduced resting and exercise heart rate while leaving contractility and conduction pathways largely unchanged.

The exact dose of Ivabradina Mylan Pharma is determined by the prescribing clinician based on the patient’s heart‑rate, clinical status, and tolerance. Dosage adjustments are made according to therapeutic response and any adverse effects, following the product’s prescribing information.

Safety data for ivabradine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies the potential risk to the fetus, and breastfeeding mothers should consult their healthcare provider before use.

To request Ivabradina Mylan Pharma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Both ivabradine and beta‑blockers lower heart rate, but ivabradine acts specifically on the If channel without affecting myocardial contractility or blood pressure, whereas beta‑blockers also reduce contractility and have broader sympathetic effects. Ivabradine is often considered when beta‑blockers are contraindicated or not tolerated.

Ivabradina Mylan Pharma tablets should be stored at temperatures below 25 °C, in the original container, protected from moisture and direct sunlight. Maintaining these conditions helps preserve tablet potency and stability throughout its shelf life.

The medication is taken orally, usually with or without food, as directed by the prescribing physician. Tablets should be swallowed whole with a glass of water and not crushed or chewed, to ensure proper absorption and effect.

The most serious risks include symptomatic bradycardia, atrial fibrillation, severe hypotension, and rare visual disturbances that may affect vision. Patients should be monitored for these events, especially during dose titration or when combined with other heart‑rate‑lowering agents.

Ivabradina Mylan Pharma is contraindicated in patients with acute decompensated heart failure, severe hypotension, sick‑sinus syndrome, or a resting heart rate below 60 bpm. It should also be avoided in individuals with known hypersensitivity to ivabradine or any of the tablet’s excipients.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 14 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.